Business Wire
01 Oct 2026, 06:30 UTC · 2h ago
Verdict
Headline takes no side. We score PFE +0.80 across one claim — strongly bullish.
+0.80strongly bullish
More positive than 89% of ticker scores this week
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
Pfizer's Phase 2 study of tilrekimig in adults with moderate-to-severe atopic dermatitis met its primary endpoint, showing a statistically significant increase in EASI-75 achievement at Week 16 across all doses.
Newpresented today via BUSINESS WIRE
So whatPositive Phase 2 data typically triggers a transition to Phase 3 trials, which will impact R&D spend over the next 12-24 months.
More positive than 93% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 89% of ticker scores this week
Positive Phase 2 study results for tilrekimig in treating atopic dermatitis.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
13h ago
—
PFE hasn't traded since this ran. Last close $28.52 (Sep 30); the reaction starts at the next open.
PFE chart →
